OP20 Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease

The Autologous Stem Cell Transplantation for Crohn’s Disease (ASTIC) trial did not achieve its ambitious primary endpoint, but reported meaningful benefits in some CD patients previously refractory or intolerant to conventional therapies. However, the haematopoietic stem cell transplantation (HSCT) regimen used was associated with a high burden of adverse events. Consequently, there is a clear need to target this therapy to patients with the...